These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22804479)

  • 1. Expert review on poliovirus immunity and transmission.
    Duintjer Tebbens RJ; Pallansch MA; Chumakov KM; Halsey NA; Hovi T; Minor PD; Modlin JF; Patriarca PA; Sutter RW; Wright PF; Wassilak SG; Cochi SL; Kim JH; Thompson KM
    Risk Anal; 2013 Apr; 33(4):544-605. PubMed ID: 22804479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.
    Famulare M; Selinger C; McCarthy KA; Eckhoff PA; Chabot-Couture G
    PLoS Biol; 2018 Apr; 16(4):e2002468. PubMed ID: 29702638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.
    Duintjer Tebbens RJ; Pallansch MA; Chumakov KM; Halsey NA; Hovi T; Minor PD; Modlin JF; Patriarca PA; Sutter RW; Wright PF; Wassilak SG; Cochi SL; Kim JH; Thompson KM
    Risk Anal; 2013 Apr; 33(4):606-46. PubMed ID: 23550968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.
    Thompson KM; Kalkowska DA; Duintjer Tebbens RJ
    Vaccine; 2015 Mar; 33(13):1568-77. PubMed ID: 25701673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
    Orenstein WA;
    Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).
    Duintjer Tebbens RJ; Pallansch MA; Kim JH; Burns CC; Kew OM; Oberste MS; Diop OM; Wassilak SG; Cochi SL; Thompson KM
    Risk Anal; 2013 Apr; 33(4):680-702. PubMed ID: 23470192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
    Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
    MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations.
    Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Ehrhardt DT; Farag NH; Hadler SC; Hampton LM; Martinez M; Wassilak SGF; Thompson KM
    Risk Anal; 2018 Aug; 38(8):1701-1717. PubMed ID: 29314143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.
    Kalkowska DA; Duintjer Tebbens RJ; Grotto I; Shulman LM; Anis E; Wassilak SG; Pallansch MA; Thompson KM
    J Infect Dis; 2015 Jun; 211(11):1800-12. PubMed ID: 25505296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative.
    Fine PE; Carneiro IA
    Am J Epidemiol; 1999 Nov; 150(10):1001-21. PubMed ID: 10568615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria.
    Kalkowska DA; Duintjer Tebbens RJ; Thompson KM
    J Infect Dis; 2014 Nov; 210 Suppl 1():S412-23. PubMed ID: 25316863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
    Duintjer Tebbens RJ; Thompson KM
    J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
    Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
    BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling population immunity to support efforts to end the transmission of live polioviruses.
    Thompson KM; Pallansch MA; Tebbens RJ; Wassilak SG; Cochi SL
    Risk Anal; 2013 Apr; 33(4):647-63. PubMed ID: 22985171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic analysis of poliovirus risk management policy options for 2013-2052.
    Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Wassilak SG; Thompson KM
    BMC Infect Dis; 2015 Sep; 15():389. PubMed ID: 26404632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses.
    Duintjer Tebbens RJ; Pallansch MA; Kalkowska DA; Wassilak SG; Cochi SL; Thompson KM
    Risk Anal; 2013 Apr; 33(4):703-49. PubMed ID: 23521018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016.
    Immunization Systems Management Group of the Global Polio Eradication Initiative
    MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(25):699-702. PubMed ID: 26135591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.